Brands, Medical Use, Clinical Data
- Analgesics, Non-Narcotic
- Antiparkinson Agents
- Antiviral Agents
- Dopamine Agents
- Capsule (100mg) and syrup
Brands / Synonyms
Adamantamine; Adamantanamine; Adamantylamine; Amantadine; Amantadine Base; Amantadine HCL; Amantidine; Aminoadamantane; Endantadine; Gen-Amantadine; Mantadine; Pk-Merz; Symadine; Symmetrel; Symmetrel
For the chemoprophylaxis, prophylaxis, and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Also for the treatment of parkinsonism and drug-induced extrapyramidal reactions.
Amantadine is an antiviral drug which also acts as an antiparkinson agent, for which it is usually combined with L-DOPA when L-DOPA responses decline (probably due to tolerance). It is a derivate of adamantane, like a similar drug rimantadine. The mechanism of action of amantadine in the treatment of Parkinson's disease and drug-induced extrapyramidal reactions is not known. It has been shown to cause an increase in dopamine release in the animal brain, and does not possess anticholinergic activity.
Mechanism of Action
The mechanism of its antiparkinsonic effect is not fully understood, but it appears to be releasing dopamine from the nerve endings of the brain cells, together with stimulation of norepinephrine response. The antiviral mechanism seems to be unrelated. The drug interferes with a viral protein, M2 (an ion channel), which is needed for the viral particle to become "uncoated" once it is taken inside the cell by endocytosis.
Amantadine is well absorbed orally from the gastrointestinal tract.
Deaths have been reported from overdose with amantadine. The lowest reported acute lethal dose was 2 grams. Drug overdose has resulted in cardiac, respiratory, renal or central nervous system toxicity. Cardiac dysfunction includes arrhythmia, tachycardia and hypertension. Pulmonary edema and respiratory distress (including ARDS) have been reported. Renal dysfunction including increased BUN, decreased creatinine clearance and renal insufficiency can occur. Central nervous system effects that have been reported include insomnia, anxiety, aggressive behavior, hypertonia, hyperkinesia, tremor, confusion, disorientation, depersonalization, fear, delirium, hallucination, psychotic reactions, lethargy, somnolence and coma. Seizures may be exacerbated in patients with prior history of seizure disorders. Hyperthermia has also been observed in cases where a drug overdose has occurred.
Biotrnasformation / Drug Metabolism
No appreciable metabolism, although negligible amounts of an acetyl metabolite have been identified.
Amantadine hydrochloride is contraindicated in patients with known hypersensitivity to the drug.
Careful observation is required when amantadine is administered concurrently with central nervous system
Coadministration of thioridazine has been reported to worsen the tremor in elderly patients with Parkinson's
disease; however, it is not known if other phenothiazines produce a similar response.
Coadministration of triamterene and hydrochlorothiazide capsules resulted in a higher plasma amantadine
concentration in a 61 year old man receiving amantadine (amantadine hydrochloride) 100 mg TID for Parkinson's
disease.1 It is not known which of the components of triamterene and hydrochlorothiazide capsules
contributed to the observation or if related drugs produce a similar response.